Syndax Pharmaceuticals Files 8-K
Ticker: SNDX · Form: 8-K · Filed: Aug 1, 2024 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, sec-filing
Related Tickers: SNDX
TL;DR
Syndax filed an 8-K on Aug 1st, check it for financial updates.
AI Summary
Syndax Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates Syndax Pharmaceuticals is providing updates on its financial condition and operations to the SEC, which is standard for public companies but may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine SEC filing for a public company and does not appear to contain immediately concerning information.
Key Players & Entities
- Syndax Pharmaceuticals Inc (company) — Registrant
- 0000950170-24-089235 (filing_id) — Accession Number
- August 01, 2024 (date) — Date of earliest event reported
- 35 Gatehouse Drive (address) — Principal Executive Offices
- Waltham, Massachusetts (location) — Principal Executive Offices
- 02451 (zip_code) — Principal Executive Offices
- 781-419-1400 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but it does not include the specific details of these results or statements.
When was this 8-K filing submitted to the SEC?
The filing was submitted on August 1, 2024, as indicated by the 'Date of Report (Date of earliest event reported)'.
What is the principal executive office address for Syndax Pharmaceuticals, Inc.?
The principal executive offices are located at Building D Floor 3, 35 Gatehouse Drive, Waltham, Massachusetts, 02451.
What is the Commission File Number for Syndax Pharmaceuticals, Inc.?
The Commission File Number for Syndax Pharmaceuticals, Inc. is 001-37708.
What is the IRS Employer Identification Number for Syndax Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Syndax Pharmaceuticals, Inc. is 32-0162505.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-08-01 16:02:10
Filing Documents
- sndx-20240801.htm (8-K) — 42KB
- sndx-ex99_1.htm (EX-99.1) — 174KB
- img199102934_0.jpg (GRAPHIC) — 14KB
- 0000950170-24-089235.txt ( ) — 364KB
- sndx-20240801.xsd (EX-101.SCH) — 25KB
- sndx-20240801_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 1, 2024, Syndax Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter and year ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNDAX PHARMACEUTICALS, INC. By: /s/ Michael A. Metzger Michael A. Metzger Chief Executive Officer Dated: August 1, 2024